These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology. Ciudin A; Hernandez C; Simó R Curr Top Med Chem; 2012; 12(6):585-604. PubMed ID: 22242856 [TBL] [Abstract][Full Text] [Related]
8. PPARγ signaling and emerging opportunities for improved therapeutics. Wang S; Dougherty EJ; Danner RL Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145 [TBL] [Abstract][Full Text] [Related]
9. Can PPARgamma agonists have a role in the management of obesity-related hypertension? Chetty VT; Sharma AM Vascul Pharmacol; 2006 Jul; 45(1):46-53. PubMed ID: 16713364 [TBL] [Abstract][Full Text] [Related]
10. Ligands for the Nuclear Peroxisome Proliferator-Activated Receptor Gamma. Sauer S Trends Pharmacol Sci; 2015 Oct; 36(10):688-704. PubMed ID: 26435213 [TBL] [Abstract][Full Text] [Related]
15. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Cho N; Momose Y Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761 [TBL] [Abstract][Full Text] [Related]
16. A review on the development in the field of NIDDM based thiazolidinedione PPARγ agonists. Banerjee PS; Samanta S Mini Rev Med Chem; 2013 Apr; 13(5):706-12. PubMed ID: 22512587 [TBL] [Abstract][Full Text] [Related]
17. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer. Lin MS; Chen WC; Bai X; Wang YD J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820 [TBL] [Abstract][Full Text] [Related]